If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
== Vehicle manufacture == Thailand ranked 11th in the world in production of motor vehicles in 2018, 2.17 million, up nine percent from 2017. Thailand output 1.95 million vehicles in 2015, ranking 12th in the world.
Upflow columns where input water enters from the bottom and regenerants enter from the top of the ion exchange column. Upflow regeneration where water enters from the top and regenerants enter from the bottom. In both cases, separate distribution headers (input water, input regenerant, exit water, and exit regenerant) must be tuned to: the input water quality and flow, the time of operation between regenerations, and the desired product water analysis. Counter-current deionization is the more attractive method of ion exchange. Chemicals (regenerants) flow in the opposite direction to the service flow. Less time for regeneration is required when compared to cocurrent columns. The quality of the finished product can be as low as .5 parts per million. The main advantage of counter-current deionization is the low operating cost, due to the low usage of regenerants during the regeneration process.
=== Direct Chemical Synthesis === Although the focus has primarily been on enzymatic approaches for overcoming length limitations with oligonucleotide synthesis, a proposed alternative is direct chemical synthesis. Standard oligo-synthesis is done on porous materials, such as controlled pore glass (CPG). However, this environment introduces challenges as sequence length increases. Longer strands take up more space within the pores and limit reagent access, which results in lower coupling efficiency and a greater number of truncated sequences in a solution. One innovative approach includes chemically synthesizing the oligonucleotides on a smooth surface, as opposed to porous material, to improve coupling efficiency while additionally utilizing the purification strategy, catching-by-polymerization (CBP), to selectively isolate full-length oligos in a solution. Performing chemical synthesis on a smooth surface, such as glass wool or glass beads, reduces steric strain and congestion, thus providing alternative solid support benefitting long-oligos.
A gelatine shot (usually called a Jell-O shot in North America and vodka jelly or jelly shot in the UK and Australia) is a shooter in which one or more liquors, usually vodka, rum, tequila, or neutral grain spirit, replaces some of the water or fruit juice that is used to congeal the gel. The American satirist and mathematician Tom Lehrer claims to have invented the gelatine shot in the 1950s while working for the National Security Agency, where he developed vodka gelatine as a way to circumvent a restriction of alcoholic beverages on base. An early published recipe for an alcoholic gelatine drink dates from 1862, found in How to Mix Drinks, or The Bon Vivant's Companion by Jerry Thomas: his recipe for "Punch Jelly" calls for the addition of isinglass or other gelatine to a punch made from cognac, rum, and lemon juice.
Sources: en.wikipedia.org
=== Compilation albums with various artists === What Feet – "Wasting My Time" (1988) Diamonds and Porcupines – "She Rides the Waves" (1988, demo version) Gigantic! 2 – "A Deeper Sleep for Steven" (1990) Indie Top 20 Vol. VIII – "Sight of You" (1990) Music for the 90's: Vol. 2 – "Time Thief" (1990, edit) Peel Session – "Time Thief" (1990) Indie Top 20 Vol XI – "Half-Life, Remembered" (1991) Knowing Where it All Leeds – "Two Sick Sisters" (1991) ...and dog bones, too – "Neverending Night" (1992) Lilliput – "Throwing Back the Apple", "Featherframe", "A Thousand Stars Burst Open" (1992, Tintwhistle Brass Band version) Precious – "Kinky Love" (1992) 4AD Presents The 13 Year Itch – "One Blue Hill" (1993, demo) All Virgos Are Mad – "Fine Friend" (1994) No Balls – "One Blue Hill" (1995) Step Right Up: The Songs of Tom Waits – "Jersey Girl" (1995) Joyride – "A Thousand Stars Burst Open" (1997) Dr. Martens Shoe Pie – "1000 Stars Burst Open" (1997) 1980 Forward – "Sight of You" (2005)
==== Doggie Kruger ==== Anubian Doggie Kruger (アヌビス星人ドギー・クルーガー, Anubisu Seijin Dogī Kurūgā), also known as "Boss" (ボス, Bosu) to several of his subordinates, is from Planet Anubis and is the tough-yet-honorable superintendent of the Space Police's Metropolitan Police, as well as chief of its Earth branch. While operating as a Dekaranger in his younger years, he earned a legendary reputation as "Hell's Guard Dog" (地獄の番犬, Jigoku no Banken), due in part to his willingness to do anything to save those he cares about. Despite this, he displays feelings for his assistant Swan and panics whenever he hears she has an admirer. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Kruger investigated the alleged corruption of his superior Kight Reidlich, and was framed for murder and held captive for two years before his team rescues him in the present. Soon after, Kruger admits his feelings for Swan. In battle, Kruger is a practitioner of the Galaxy Sword-Style (銀河一刀流, Ginga Ittō-ryū) where he learned the style's secret technique, the Vega Impulse (ベガインパルス, Bega Inparusu). Though he is capable of destroying 100 foes without being defeated, he suffered from a spinal problem that caused him to miss once every 2000 attacks until being cured by chiropractor Yukito Sanjyo of the Abarangers. Additionally, utilizing a variant of the SP License called the Master License (マスターライセンス, Masutā Raisensu), Kruger can transform into the black-colored Deka Master (デカマスター, Deka Masutā).
Douyin (Chinese: 抖音; pinyin: Dǒuyīn; lit. 'Shaking Sound') was launched on 20 September 2016, by ByteDance, originally under the name A.me, before changing its name to Douyin in December 2016. Douyin was developed in nearly 7 months and within a year had 100 million users, with more than one billion videos viewed every day. While TikTok and Douyin share a similar user interface, the platforms operate separately. Douyin includes an in-video search feature that can search by people's faces for more videos of them, along with other features such as buying, booking hotels, and making geo-tagged reviews.
Sources: en.wikipedia.org
=== Qualitative analysis === Generally, chromatographic data is presented as a graph of detector response (y-axis) against retention time (x-axis), which is called a chromatogram. This provides a spectrum of peaks for a sample representing the analytes present in a sample eluting from the column at different times. Retention time can be used to identify analytes if the method conditions are constant. Also, the pattern of peaks will be constant for a sample under constant conditions and can identify complex mixtures of analytes. However, in most modern applications, the GC is connected to a mass spectrometer or similar detector that is capable of identifying the analytes represented by the peaks.
These genes can be placed in three categories: genes that increase the risk of migraine in general, those that specifically increase risk for migraine with aura, and those that specifically increase risk for migraine without aura. Three of these genes, CALCA, CALCB, and HTR1F, are already targets for migraine specific treatments. Five genes are specific to risk of migraine with aura, PALMD, ABO, LRRK2, CACNA1A and PRRT2, and 13 genes are specific to risk of migraine without aura. Using the accumulated genetic risk of common variations to calculate a so-called polygenetic risk score, it is possible to assess, for example, the treatment response to triptans.
Amine groups are found throughout an antibody and are used as a target due to their easy steric accessibility and modification. An overview of this reaction is found in Figure 2. Most often amine groups found on lysine are covalently bonded to carboxyl groups of glutamic and aspartic acid on formed liposomes using certain agents. A two step process is utilized where the first step uses 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide to create an amine reactive product from the carboxyl group. This product is a target for a nucleophilic attack by the amine but it hydrolyzes quickly, so EDC is added to stabilize it. As seen in the Figure 2, the intermediate can lead to the desired stable amide bond by chance or the recreation of a carboxyl group. To create more of the desired carboxyl-amine bond, N-hydroxysulfosuccinimide (sulfo-NHS) is added to form another intermediate that is an NHS ester. The second step to this reaction is for the antibodies to use the N-terminus of the lipid to covalently conjugate by creating an amide bond via displacement of sulfo-NHS groups. This leads to the final product of an antibody conjugated to a liposome to create an immunoliposome. This process is highly efficient and effective while maintaining the biological activity of the antibody.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.